Serina Therapeutics, Inc.
Serina Therapeutics, Inc. (NYSE: SER) is a clinical-stage biotechnology company developing drug candidates that use its proprietary poly(2-oxazoline), or POZ, polymer delivery technology. POZ is designed to modify small molecules, RNA-based therapeutics and antibody-drug conjugates to control drug loading and release;… From the company’s description.
Over the twelve months to Jun 30, 2026, Serina Therapeutics, Inc. reported a net loss of $21.18M. Operations used $21.14M in cash. In fiscal 2025, it reported revenue of $0.13M, up 132.1% from fiscal 2024, and a net loss of $19.21M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Serina Therapeutics, Inc. does
In the company’s own words
Serina Therapeutics, Inc. (NYSE: SER) is a clinical-stage biotechnology company developing drug candidates that use its proprietary poly(2-oxazoline), or POZ, polymer delivery technology. POZ is designed to modify small molecules, RNA-based therapeutics and antibody-drug conjugates to control drug loading and release; the company’s candidates target neurological diseases, particularly Parkinson’s disease. Its lead candidate, SER 252, is a POZ-apomorphine conjugate being studied for advanced Parkinson’s disease and designed for long-acting subcutaneous administration; the company began a Phase 1b trial in February 2026. SER 214, a POZ-rotigotine candidate, completed a Phase 1a study and is not being advanced internally. Serina is also conducting preclinical work on POZ lipids for lipid nanoparticle delivery of RNA and licenses its POZ technology to partners, including Pfizer for a specific lipid nanoparticle application. Its business is organized around research and development of its pipeline and platform rather than reportable operating segments. The company was formed to develop a polymer alternative to polyethylene glycol for pharmaceutical applications. Its website is https://serinatx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- HUNTSVILLE, AL
- Fiscal year end
- December
- CIK
- 1708599
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Serina Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Serina Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Serina Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Serina Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Serina Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”